A weight-loss and diabetes drug may do more than help people manage blood sugar or body weight. In a small early study, the GLP-1 receptor agonist liraglutide cut monthly migraine days by about half in adults with obesity and chronic migraine, raising hope that drugs in the same broad family as Ozempic and Wegovy could one day open a new path for migraine prevention.
The study, presented at the European Academy of Neurology Congress 2025 and published in the journal Headache, tested liraglutide in 26 adults with obesity and chronic migraine. According to News Medical, participants reported an average of 11 fewer headache days per month after 12 weeks of treatment, while migraine-related disability scores improved meaningfully.
That sounds exciting, but the key phrase is “small study.” The results are promising, not definitive. There was no large randomized placebo-controlled trial yet, and migraine studies can be strongly affected by placebo response, expectation, lifestyle changes, and natural symptom fluctuation. Still, the finding is notable because the benefit appeared to happen with little weight loss, suggesting the drug may be acting through a mechanism beyond simply reducing body weight.
What Drug Was Studied?
The drug studied was liraglutide, a GLP-1 receptor agonist used for type 2 diabetes and weight management. It is sold under brand names including Victoza for diabetes and Saxenda for weight management in some markets.
GLP-1 drugs mimic or enhance the action of glucagon-like peptide-1, a hormone involved in blood sugar control, appetite, digestion, and metabolic signaling. Newer GLP-1 and related drugs, including semaglutide and tirzepatide, have become widely known because of their large weight-loss effects.
The migraine study did not test Ozempic, Wegovy, Mounjaro, or Zepbound directly. It tested liraglutide. That distinction matters because drugs in the same family can have different doses, schedules, effects, side effects, and brain or fluid-pressure activity.
Who Was in the Study?
The study included 26 adults with obesity and chronic migraine. Chronic migraine is usually defined as headache on 15 or more days per month, with migraine features on at least eight of those days. People with chronic migraine often live with pain, light sensitivity, nausea, brain fog, missed work, sleep disruption, and repeated medication use.
These were not people with occasional headaches. They had a high migraine burden and had not responded well enough to existing preventive treatments. That makes the reported improvement more interesting, because treatment-resistant chronic migraine is difficult to manage.
Still, 26 people is a very small sample. A study that size can detect an early signal, but it cannot prove that the drug works for the broader migraine population. It also cannot fully identify rare side effects or predict how different patient groups would respond.
How Much Did Migraine Days Drop?
Researchers reported that participants had an average reduction of 11 monthly headache days during the 12-week observation period. In practical terms, that is a major change for someone living with chronic migraine.
A person who has headaches on 20 days per month and drops to nine days may regain work time, family time, sleep, and daily function. Migraine is not just pain. It can affect mood, concentration, social life, income, and independence.
Disability scores also improved. News Medical reported that scores on the Migraine Disability Assessment Test fell by 35 points, suggesting better functioning in work, school, and social activities. That kind of quality-of-life improvement is often as important as the raw headache-day count.
Why the Weight-Loss Angle Is Complicated
Because liraglutide is known as a diabetes and weight-loss drug, it is natural to assume migraine improvement came from losing weight. But the study suggests that may not be the main explanation.
Participants’ average body-mass index dropped only slightly, from 34.01 to 33.65, and the change was not statistically significant. Researchers reported that BMI reduction did not explain the reduction in headache frequency.
That is important because obesity and migraine are linked in complex ways. Weight loss can help some people with migraine, but this study raises the possibility that liraglutide may affect migraine biology more directly.
The proposed mechanism involves brain fluid pressure and cerebrospinal fluid regulation, not just appetite suppression.
The Brain-Pressure Theory
Researchers believe liraglutide may reduce migraine frequency by lowering cerebrospinal fluid pressure or influencing intracranial pressure dynamics. This idea comes partly from research on idiopathic intracranial hypertension, a condition in which pressure inside the skull is elevated and headache is common.
A 2023 study in Brain found that the GLP-1 receptor agonist exenatide reduced intracranial pressure in people with idiopathic intracranial hypertension. That earlier work, available through PubMed Central, helped build interest in whether GLP-1 drugs might influence headache disorders through fluid-pressure pathways.
The Naples research team suggested that lowering cerebrospinal fluid secretion or pressure could reduce stress on pain-sensitive structures and dampen migraine-related signaling. This is still a hypothesis, but it is scientifically interesting because it points to a migraine pathway that is different from many current treatments.
How This Differs From Current Migraine Drugs
Many modern migraine preventives target calcitonin gene-related peptide, known as CGRP, or its receptor. CGRP plays a major role in migraine pain signaling, and CGRP-blocking injections and pills have helped many patients.
Other preventives include beta blockers, anti-seizure medications, antidepressants, Botox injections for chronic migraine, and neuromodulation devices. These treatments can help, but they do not work for everyone, and some people stop because of side effects or limited benefit.
A GLP-1-based migraine treatment would be different if future trials confirm the pressure-modulation theory. It would not replace existing migraine therapies immediately, but it could become another option for patients who do not respond to current preventives.
The American Migraine Foundation explains that preventive treatment is often considered when migraine attacks are frequent, disabling, or not controlled with acute medicines. A new preventive pathway would be especially meaningful for people with chronic or treatment-resistant migraine.
Why the Placebo Question Matters
Migraine studies often show strong placebo effects. People may improve because they expect improvement, because they are monitored more closely, because they change routines during the study, or because migraine frequency naturally rises and falls over time.
That does not mean the liraglutide finding is meaningless. It means the next trial must be stronger. A randomized, double-blind, placebo-controlled study would compare liraglutide with an inactive injection while neither patients nor researchers know who received which treatment.
That kind of design is needed to separate the drug’s true effect from expectation and study participation. Researchers have already indicated that a randomized trial with direct or indirect intracranial-pressure measurement is being planned.
Why the Study’s Short Duration Matters
The study lasted 12 weeks. That is enough to detect early improvement, but migraine is a long-term condition. Patients and doctors need to know whether the benefit lasts for six months, one year, or longer.
Longer studies would also help clarify whether side effects increase, decrease, or change over time. GLP-1 drugs often cause gastrointestinal symptoms, especially during dose escalation. Some patients adjust, while others cannot tolerate the drug.
For migraine prevention, tolerability matters because preventive drugs are taken regularly. A treatment that reduces migraine days but causes constant nausea may not be acceptable for many patients.
What Side Effects Were Reported?
In the small liraglutide migraine study, mild gastrointestinal side effects were reported in 38% of participants, mainly nausea and constipation. No participant stopped treatment because of those side effects, according to the study summary.
That is encouraging, but the small sample limits safety conclusions. GLP-1 drugs can cause nausea, vomiting, diarrhea, constipation, reduced appetite, abdominal discomfort, dehydration, gallbladder problems, and other adverse effects in some patients. Rare but serious risks vary by drug and patient profile.
The U.S. Food and Drug Administration provides safety information on GLP-1 receptor agonists and emphasizes that patients should use these medicines under medical supervision.
Why This Is Not a Reason to Self-Medicate
People with migraine should not start a GLP-1 drug on their own for headache prevention. These drugs require medical evaluation, prescription oversight, dose management, and monitoring. They may not be appropriate for people with certain medical histories, gastrointestinal disorders, pancreatitis risk, gallbladder disease, pregnancy plans, or medication interactions.
Also, not all GLP-1 drugs are the same. The study tested liraglutide, not every drug in the class. It is too early to assume semaglutide, tirzepatide, or other GLP-1 medications will produce the same migraine benefit.
People already taking GLP-1 medicines who notice migraine changes should discuss them with their healthcare provider rather than changing dose or stopping suddenly.
Why Migraine Needs More Treatment Options
Migraine is one of the most disabling neurological disorders worldwide. It can cause severe throbbing pain, nausea, vomiting, light sensitivity, sound sensitivity, visual symptoms, dizziness, and cognitive problems. For people with chronic migraine, the disease can dominate daily life.
The World Health Organization describes headache disorders, including migraine, as among the most common nervous-system disorders. Migraine can reduce quality of life, work productivity, and social participation.
Existing treatments help many people, but gaps remain. Some patients do not respond. Some cannot tolerate side effects. Some cannot access newer drugs because of cost or insurance restrictions. That is why repurposing an already approved drug class is attractive.
Why Obesity and Migraine Are Connected
Obesity is associated with a higher risk of frequent and chronic migraine, though the relationship is complex. Inflammation, hormones, sleep apnea, insulin resistance, physical activity, mood disorders, medication use, and pain pathways may all contribute.
Weight loss can reduce migraine burden in some people, but it is not a universal cure. Many people with migraine are not obese, and many people with obesity do not have migraine. The liraglutide study focused on adults with both obesity and chronic migraine, so the results may not apply to all migraine patients.
Future studies will need to test whether people without obesity also benefit, whether people with high-frequency episodic migraine respond, and whether benefit depends on baseline intracranial pressure or metabolic markers.
Why Intracranial Pressure Is Getting More Attention
Intracranial pressure has traditionally been associated with conditions such as idiopathic intracranial hypertension, brain injury, tumors, and hydrocephalus. But researchers are increasingly exploring whether subtle pressure changes may influence migraine in some patients.
The idea is not that all migraine is caused by high brain pressure. Migraine is a complex neurological disease with genetic, vascular, inflammatory, sensory, hormonal, and environmental components. But a subgroup of patients may have pressure-sensitive biology that responds to GLP-1 drugs.
If that is true, future migraine treatment may become more personalized. Instead of giving every patient the same sequence of preventives, doctors may use symptoms, imaging, eye exams, biomarkers, or pressure-related clues to choose treatment.
What Researchers Need to Prove Next
The next step is a larger randomized trial. Researchers need to show that liraglutide works better than placebo, that the effect is clinically meaningful, and that the benefit is safe and durable. They also need to measure whether intracranial pressure actually changes in patients whose migraines improve.
Researchers should also compare liraglutide with existing preventive treatments or test it as an add-on therapy. That would help answer whether it is best for people who have failed other drugs, people with obesity and migraine, people with signs of pressure sensitivity, or a broader migraine population.
A strong trial would also track weight change, nausea, constipation, medication use, quality of life, emergency visits, work productivity, and migraine-specific symptoms.
Why the Result Still Matters
Even with all the caveats, the study matters because it hints at a new migraine pathway. Many migraine drugs target pain signaling or vascular-neurological pathways. Liraglutide may be working through fluid-pressure modulation, which would be a different angle.
That could be especially important for people with chronic migraine who have tried multiple treatments without enough relief. For them, even a small chance of a new therapeutic pathway is meaningful.
The result also fits a broader trend. GLP-1 drugs are being investigated for conditions beyond diabetes and obesity, including cardiovascular disease, kidney disease, fatty liver disease, sleep apnea, addiction, inflammation, and neurological disorders. Some of those uses are supported by strong evidence. Others remain early and experimental.
Why Headlines Should Stay Careful
It is tempting to say a weight-loss drug “cuts migraine days in half.” That is what happened on average in this small study, but the wording needs caution. A better interpretation is that liraglutide was associated with a large reduction in monthly headache days in a 26-person pilot study.
That difference matters because patients may read the headline and expect the same result. Real-world medicine is rarely that simple. Some people may respond strongly. Some may not respond at all. Some may stop because of side effects. Some may not be eligible for the drug.
The study is hopeful, but it is not yet practice-changing.
Final Takeaway
A small early study found that liraglutide, a GLP-1 drug used for diabetes and weight management, reduced monthly migraine days by about half in adults with obesity and chronic migraine. Participants reported an average of 11 fewer headache days per month after 12 weeks, with improved migraine-related disability scores.
The most interesting part is that the benefit did not appear to be driven mainly by weight loss. Researchers believe liraglutide may affect migraine by lowering cerebrospinal fluid pressure or changing intracranial-pressure dynamics, opening a possible new pathway for migraine prevention.
The finding is promising but preliminary. The study involved only 26 people, lasted 12 weeks, and needs confirmation in larger randomized placebo-controlled trials. For now, people with migraine should not use GLP-1 drugs off-label without medical guidance, but the research gives scientists a new direction to explore for patients who still need better migraine options.
